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Gastrointestinal stromal tumours (GISTs) are the most 
common nonepithelial neoplasm of the gastrointestinal tract. 
Because GISTs share CD117 positivity with the interstitial cells 
of Cajal, they were assumed to originate from that cell type.1 
GISTs almost uniformly express the tyrosine kinase receptor, 
KIT, which is encoded by the proto-oncogene KIT, located on 
chromosome 4q11–12.2 Activation of KIT by its ligand leads 
to the activation of networks of signal transduction pathways 
which control cell proliferation, survival, apoptosis and other 
cell functions.3 Tyrosine kinase receptor [platelet-derived 
growth factor receptor alpha (PDGFRα)] mutations have been 
documented in a small group of GISTs. Mutually exclusive 
gain-of-function KIT or PDGFRα mutations are central events 
in the pathogenesis of GISTs.4,5 So far, predictive factors for 
the prognosis of patients with GISTs are mainly based on the 
macroscopic and microscopic features of the tumours.6 The 
predictive value of the gene mutations is still unclear. The 
aims of the study were to analyse the relationship between the 
expression of KIT and PDGFRα mutations and the phenotype 
of the GISTs in a series of resected patients, and to explore the 
potential role of gene mutations as an adjunctive prognostic 
factor.
Method
Patient population
The study included 30 patients who underwent an operation 
for a GIST. There were 15 women and 15 men, with a mean 
age of 67 years, and an age range of 16–90 years. The mean 
size of the tumours was 8 cm in diameter, with a range of 
0.5–21.0 cm. The tumours were located in the stomach (n 
= 16), small bowel (n = 9), duodenum (n = 1), left colon 
(n = 1), peritoneum (n = 2) and spleen (n = 1). The GISTs 
were discovered incidentally in 18 patients during diagnostic 
imaging studies or surgeries performed for other reasons. 
Acute tumours were diagnosed in 12 patients because of 
a life-threatening condition (gastrointestinal bleeding, 
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bowel obstruction or perforation). On presentation, three 
patients exhibited hepatic metastasis. Peritoneal and omental 
metastases were reported in two patients, and there was 
tumour involvment in both the liver and peritoneum in one 
patient. 
Histology and immunohistochemistry
The specimens were examined by using light microscope 
morphology analysis after haematoxylin-eosin staining. The 
diagnosis of GIST was confirmed by immunohistochemical 
investigations, including antibody tests for CD34, CD117, 
vimentin, desmin, smooth muscle actin (SMA) and S-100 
tumour markers.
Molecular biology
The molecular profiles were screened to indicate genetic 
mutations. Exons 9, 11, 13 and 17 of KIT, and exons 12 
and 18 of PDGFRα, were evaluated by PCR and the Sanger 
sequencing method for tumour DNA. Molecular analysis of 
the tumour samples was performed by DNA extraction from 
paraffin-embedded tissue, the amplification of the DNA 
by PCR, direct genomic sequencing according to Sanger’s 
procedure, and data examination. The genomic sequencing 
was performed by using Genetic Analyzer® 3130, with 
Sequencing Analysis® Software, version 5.2.
Risk assessment
The risk assessment of the tumours was evaluated by applying 
the criteria of Miettinen and Lasota/ Armed Forces Institute of 
Pathology criteria. Patients were divided into four prognostic 
groups (very low, low, intermediate and high risk) by tumour 
size, location and mitotic rate as variables in order to evaluate 
the likelihood of GIST malignant behaviour (Table 1).6
Results
Patients received laparoscopic or open surgery, depending on 
the tumour size, primary location of the GIST and the presence 
of metastases (Table 2). R0 resection was achieved in 27 
patients (90%), but three of them required a hepatic resection 
to remove liver metastases. Only a gross resection of the 
primary malignancy was obtained (R2) in the remaining three 
patients because there was extensive spread of the tumour 
to the peritoneal cavity. Extended node dissection is not 
indicated in surgery for GISTs, and it was never performed. 
Postoperative mortality did not occur. Morbidity was reported 
in three patients [pulmonary embolism (n = 1), perihepatic 
abscess treated with percutaneous ultrasound-guided drainage 
(n = 1) and postoperative hemorrhage requiring relaparotomy 
(n = 1)]. 
Morphologically, the tumours displayed a spindle cell type 
(n = 13), epitheloid type (n = 10) and mixed populations 
cells (n = 7). CD117 expression was immunohistochemically 
documented in 100% of the GISTs, and CD34 in 24 patients 
(80%). Other markers, such as vimentin, desmin, SMA and 
S-100, were detected in a sporadic manner. The mitotic rate 
of the tumours was ≥ 5/50 high-power fields (HPFs) in 10 
patients, and ≤ 5/50 HPFs in 16. There was no detectable 
mitotic activity in the tumours of four patients.
Twenty-three tumours (77%) proved to be affected by KIT 
(n = 18) or PDGFRα mutations (n = 5), while seven tumours 
were wild type. Exon 11 was involved in 15 cases, and exon 
9 and exon 17 in one case each, in the GISTs with KIT 
mutation. Both exon 9 and exon 17 were involved in a further 
case of KIT mutation. There was exon 18 involvement in all 
five GISTs that harboured PDGFRα mutations.
The average diameter of the tumours carrying mutations 
in KIT was 8.7 cm, compared to 5.4 and 5.9 cm for tumours 
carrying PDGFRα mutations and the wild type, respectively. 
KIT gene mutations were shown in nine of the 10 patients with 
a tumour exceeding 10 cm in diameter. There was a mutatated 
KIT gene in 50% of the gastric GISTs, and in ≥ 70% of the 
bowel and extravisceral GISTs. KIT gene mutations were 
found in seven of the 10 tumours with a mitotic rate ≥ 5/50 
HPFs (70%), 10 of 16 with a mitotic rate ≤ 5/50 HPFs (63%), 
and one of four tumours with no mitotic activity (25%). In 
Table 1: Risk assessment of gastrointestinal stromal tumours, using Miettinen and Lasota/Armed Forces Institute of 
Pathology criteria6
Risk class Features
Very low, if any, malignant potential ≤ 2 cm and ≤ 5 (mitotic index)*
Low malignant potential
Gastric: ≥ 2 cm and ≤ 10 cm, and ≤ 5 (mitotic index)  
≤ 2 cm and ≥ 5 (mitotic index)
Intestinal: ≥ 2 cm and ≤ 5 cm, and ≤ 5 (mitotic index)
Intermediate malignant potential
Gastric: ≥ 10 cm and ≤ 5 (mitotic index)  
≥ 2 cm and ≤ 5 cm, and ≥ 5 (mitotic index)
Intestinal: ≥ 5 cm and ≤ 10 cm, and ≤ 5 (mitotic index)
High malignant potential
Gastric: ≥ 5 cm and ≥ 5 (mitotic index)
Intestinal: ≥ 10 cm or ≤ 5 (mitotic index)
*: Mitotic index = number of mitoses per 50 high-power fields
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addition, four of the six tumours that metastasised expressed 
KIT mutations. The five cases with mutation of the PDGFRα 
gene were all located in the stomach, and had a mitotic rate 
≤ 5/50 HPFs. The allocation of tumours on the basis of the 
risk assessment criteria for GISTs by Miettinen and Lasota 
is shown in Table 3, together with the molecular analysis.6 
Accordingly, nine patients were classified as having very low-, 
five as low-, five as intermediate-, and 11 as high-risk tumours 
(Table 4). High- and intermediate- risk patients were given 
target therapy with imatinib mesylate or sunitinib following 
an oncological consultation.
Discussion
GISTs are the most common mesenchymal tumours of the 
gastrointestinal tract. Since they were recognised as a distinct 
neoplasm from myogenic and neurogenic tumours, many 
studies have focused on classification criteria to subdivide this 
heterogeneous tumour group into benign and malignant GISTs. 
Since the introduction of the therapeutic armamentarium of 
Table 2: Primary location and surgeries in patients with gastrointestinal stromal tumours
Primary GIST location Surgery Cases (n = 30)
Stomach (n = 16)
Wedge resection 8
Partial gastrectomy 5
Partial gastrectomy plus hepatic resection 1
Total gastrectomy 1
Total gastrectomy plus hepatic resection 1
Small bowel (n = 10)
Jejunoileal resection 6
Jejunoileal resection plus hepatic resection 1
Wedge resection 2
Ileocolic resection 1
Other (n = 4)
Peritonectomy plus small bowel resection 2
Left colectomy 1
Splenectomy 1
GIST: gastrointestinal stromal tumour
Table 3: The clinicopathological features of patients with gastrointestinal stromal tumours (n = 30)
Mutation Patients,  n (%)
Primary 
location Points
Tumour size 
(cm) Points Mitotic index Points
None 7 (23)
Stomach 
Small bowel 
Peritoneum
3 
3 
1
≤ 2 
2–5 
5–10 
≥ 10
1 
3 
1 
2
≤ 5 x 50 HPFs 
≥ 5 x 50 HPFs
4 
3
c-KIT 18 (60)
Stomach 
Small bowel 
Peritoneum 
Spleen 
Large bowel
8 
7 
1 
1 
1
≤ 2  
2–5 
5–10 
≥ 10
1 
6 
3 
8
≤ 5 x 50 HPFs 
≥ 5 x 50 HPFs
11 
7
PDGFRα 5 (17) Stomach 5
≤ 2  
2–5 
5–10 
≥ 10
1 1 
3 
0
≤ 5 x 50 HPFs 
≥ 5 x 50 HPFs
5 
0
HPFs: high-power fields, PDGFR: platelet-derived growth factor receptor alpha
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imatinib (a tyrosine kinase inibitor which blocks the kinase 
activity of KIT and PDGFRα genes), the risk assessment of 
GISTs has become increasingly important. Selected patients 
with resectable primary GISTs may be offered imatinib 
treatment after surgery, but it has to be demonstrated that the 
tumours have features suggestive of an aggressive course. 
The USA National Institute of Health consensus criteria 
were first applied to estimate the risk of aggressive GIST 
behaviour.7 Applying these criteria, the high-risk category 
includes tumours ≥ 10cm, regardless of mitotic activity, 
tumours of any size when the mitotic activity exceeds 10/50 
HPFs, and tumours ≥ 5cm when the mitotic count exceeds 5/50 
HPFs. Miettinen and Lasota proposed a further model of risk 
stratification, which takes into account the site of the tumour 
as an adjunct to tumour size and mitotic activity. Generally, 
gastric GISTs are associated with a better outcome than 
intestinal GISTs.6 Recently, tumour rupture on presentation 
or during surgery was proposed as a further independent 
prognostic factor for survival in patients with GIST.8
The detection of gain-of-function mutations in the gene 
encoding the KIT receptor, and rare mutations in PDGFRα, 
was the hallmark of understanding the biology of GISTs.4,5 
Gene mutation rates in GIST have been estimated to range 
from 21–57% for KIT,9,10 and from 5–15% for PDGFRα.11 It 
was shown in data from this study that 77% of patients with 
GISTs had gene mutations, of which 60% were in KIT, and 
17% in the PDGFRα genes. Whether or not KIT/PDGFRα 
mutations influence the outcome of patients with GIST has 
been previously investigated, but definitive results are still 
lacking. The aim of investigations was to specifically evaluate 
the relationship between the presence of mutations in the KIT 
gene, mostly involving exon 11, and the malignant behaviour 
of the GIST.12 A poor prognosis for exon 11 mutations has 
been suggested by the findings in several studies,9,10,13 but 
has not been confirmed universally.14–17 In addition, the 
prognostic significance of the type of mutation of exon 11 
(missense versus others) is unclear, although deletions and 
insertions have been shown to carry a greater risk with respect 
to recurrence-free survival. By contrast, the presence of 
PDGFRα gene mutations, mostly affecting exon 18, relates to 
less aggressive GIST behaviour.18
It was observed in our study that KIT-mutated GISTs were 
located in the stomach, as well as at extragastric sites, i.e. the 
small bowel, large bowel and peritoneum. The latter locations 
were linked to a more adverse prognosis.19,20 Four of the six 
tumours that were metastatic on presentation harboured KIT 
mutations. Conversely, all the observed cases of GIST with 
PDGFRα-mutated genes originated from the stomach. where 
tumours are inclined to be less aggressive. None of them 
had metastasised. It was reported in a recent study in which 
the focus was a series of 346 gastric GISTs, that PDGFRα 
mutations occurred in 35% of the tumours, were associated 
with a lower mitotic index, and had a benign course in more 
than 80% of cases.21 The observed rate of PDGFRα mutation 
in the intestinal GIST was 3% in the same study. The low 
potential of PDGFRα-mutated GIST to metastasise has been 
emphasised in other reports.22,23
The size of the tumour is a negative predictor of GIST 
behaviour.24 Tumours harbouring mutations on the KIT gene 
in our study had a greater diameter with respect to PDGFRα-
mutated and wild-type GISTs. Mutations in KIT were shown 
in nine of 10 patients with a GIST size ≥ 10cm, whereas none 
of the patients with KIT gene mutation had a tumour size 
≤ 2cm. 
Although based on a limited number of cases, the data 
from our study also suggest a link between KIT mutation and 
tumour mitotic index. Mutations were found in 70% of the 
GISTs with a mitotic index ≥ 5/50 HPFs, 63% of GISTs with 
a mitotic activity ≤ 5/50 HPFs, and in 25% of GISTs with no 
mitotic activity. 
A more aggressive phenotype for GISTs harbouring KIT 
mutations has previously been reported. These tumours are 
larger in size, inclined to invade nearby tissues and organs, 
are associated with higher mitotic figures and carry a worse 
prognosis.10,13 By contrast, the presence of KIT mutations is 
not constantly linked to phenotypic features predictive of poor 
outcome. For example, a correlation between KIT mutation 
and tumour size, mitotic count or a different prognosis, could 
not be shown in some investigations.9,17 
KIT mutations were frequently seen in GISTs classsified as 
high risk in the present study. However, this same molecular 
alteration was demonstrated even in tumours in lower classes 
Table 4: The distribution of c-KIT and PDGFRα mutations in four risk classes, according to Miettinen and Lasota6
Risk class Wild type c-KIT PDGFRα Total
Very low 3 4 2 9
Low 0 2 3 5
Moderate 1 4 0 5
High 3 8 0 11
Total 7 18 5 30
PDGFRα: platelet-derived growth factor receptor alpha
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of risk, making the prognostic role of KIT mutations unclear. 
Conversely, PDGFRα mutations were expressed by GISTs 
in the very low- and low-risk classes. A link between this 
molecular feature and a better outcome is implied by this 
observation. The observation of a more frequent KIT mutation 
in high-risk tumours, and the prevalence of PDGFRα 
mutation in tumours belonging to lower-risk classes, has been 
confirmed elsewhere.5,24,25
Data from our study were insufficient to predict the risk 
through the analysis of specific subgroups of KIT mutations. 
A poor oncological outcome associated with KIT exon 9 
mutations has been reported in previous studies,19,20 although 
this observation has not been confirmed elsewhere.26,27 
The risk of GISTs with exon 9 mutations was linked to the 
preferred location of this genotype in the small bowel, rather 
than to underlying mutation, in a recent study.28 For example, 
exon 9 KIT-mutated GISTs located in the small bowel were an 
average size of 7cm, whereas GISTs with the same genotype 
mutation, but which had developed in the stomach, were an 
average size of 4cm. 
Surgical R0 resection of a localised GIST is still the first 
choice of treatment. However, tumour recurrence is not a 
rare event in GISTs where five-year recurrence-free survival 
ranges from 63–78%. Tumours at high risk of recurrence 
may benefit from adjuvant therapy, even when completely 
excised at surgery. With this in mind, efforts should be made 
to increase the ability to predict the likelihood of recurrence 
following surgery. The commonly used staging systems 
for risk assessment have shown to be reliable in predicting 
the clinical behaviour of tumours, but sometimes they fail. 
Tumours in either low- and high-risk groups may behave 
unexpectedly, suggesting that current searching variables 
employed by the standard prognostic models are unable to 
assign certain GISTs to a defined risk category.29-31 Molecular 
analysis is an additional tool to assist in stratifying and 
treating GISTs.
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